Alexion Pharmaceuticals (NASDAQ:ALXN)‘s stock had its “buy” rating reissued by research analysts at Credit Suisse Group in a research note issued to investors on Thursday. They presently have a $147.00 price target on the biopharmaceutical company’s stock. Credit Suisse Group’s price target indicates a potential upside of 20.37% from the stock’s previous close.

Several other equities analysts also recently issued reports on the stock. Raymond James Financial restated an “outperform” rating and issued a $130.00 price objective (down previously from $178.00) on shares of Alexion Pharmaceuticals in a research note on Thursday, January 4th. They noted that the move was a valuation call. UBS Group downgraded shares of Alexion Pharmaceuticals from a “strong-buy” rating to an “outperform” rating in a research note on Thursday, January 4th. BidaskClub upgraded shares of Alexion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, December 27th. Robert W. Baird upgraded shares of Alexion Pharmaceuticals from a “neutral” rating to an “outperform” rating and set a $150.00 price objective for the company in a research note on Monday, December 18th. Finally, Leerink Swann restated a “buy” rating and issued a $169.00 price objective on shares of Alexion Pharmaceuticals in a research note on Wednesday, December 6th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and nineteen have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $153.10.

Alexion Pharmaceuticals (ALXN) opened at $122.12 on Thursday. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.51 and a current ratio of 2.96. The company has a market cap of $27,810.03, a price-to-earnings ratio of 54.52, a P/E/G ratio of 1.04 and a beta of 1.18. Alexion Pharmaceuticals has a 12 month low of $96.18 and a 12 month high of $149.34.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.44 EPS for the quarter, topping analysts’ consensus estimates of $1.32 by $0.12. The firm had revenue of $859.00 million during the quarter, compared to the consensus estimate of $864.34 million. Alexion Pharmaceuticals had a net margin of 14.57% and a return on equity of 12.55%. The company’s revenue was up 7.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.23 earnings per share. analysts expect that Alexion Pharmaceuticals will post 4.82 EPS for the current year.

In related news, CEO Ludwig Hantson sold 2,553 shares of the stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $121.63, for a total transaction of $310,521.39. Following the completion of the transaction, the chief executive officer now directly owns 36,172 shares of the company’s stock, valued at $4,399,600.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 4.35% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of ALXN. Valeo Financial Advisors LLC purchased a new position in Alexion Pharmaceuticals during the third quarter worth about $147,000. Dupont Capital Management Corp acquired a new position in Alexion Pharmaceuticals during the third quarter worth about $156,000. BT Investment Management Ltd acquired a new position in Alexion Pharmaceuticals during the third quarter worth about $165,000. YorkBridge Wealth Partners LLC grew its position in Alexion Pharmaceuticals by 221.7% during the second quarter. YorkBridge Wealth Partners LLC now owns 1,425 shares of the biopharmaceutical company’s stock worth $173,000 after buying an additional 982 shares during the period. Finally, Beacon Investment Advisory Services Inc. acquired a new position in Alexion Pharmaceuticals during the third quarter worth about $201,000. 94.27% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This report was published by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The correct version of this report can be accessed at https://www.americanbankingnews.com/2018/01/18/credit-suisse-group-reaffirms-buy-rating-for-alexion-pharmaceuticals-alxn.html.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.